Update on triplet therapy with ivosidenib, venetoclax, and azacitidine

During the 2022 ASCO Annual Meeting, the AML Hub spoke with Curtis Lachowiez, MD Anderson Cancer Center, Houston, US. We asked...

Real-world prognostic significance of pretransplant NGS-MRD testing

The pre-MEASURE study is the largest dataset of NGS-MRD reported to date, in which the clinical use of NGS-MRD was validated using...

The impact of IDH2 mutant allele (R140/R172) on survival outcomes with enasidenib: An update from the IDHENTIFY trial

Mutations in the isocitrate dehydrogenase 2 (IDH2) gene occur in around 8–19% of...

ASCO22 Annual Meeting roundup – Ivosidenib

We summarize three poster presentations from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which covered safety data on Ivo +...

Decitabine shows comparable OS to standard induction chemotherapy and better safety in patients with AML

Lübbert et al. investigated the efficacy and safety of a 10-day decitabine regimen compared to...

Quizartinib, decitabine, and venetoclax combination therapy in patients with AML and prior exposure to FLT3 inhibitors

During the European Hematology Association (EHA) 2022 Congress, the triplet...

Does 10-day decitabine improve post-transplant outcomes in older patients compared with 3+7 chemo?

Ossenkoppele begins by introducing the study presented at the congress, outlining the study design...

The QuANTUM-First trial

During the EHA 2022 Congress, the AML Hub was pleased to speak with Hee-Je Kim, The Catholic University of Korea, Seoul, KR, about the initial findings from the QuANTUM-First...

The NOPHO-DB-SHIP consortium recommendations for supportive care in pediatric AML

A summary of recommendations published in Expert Review of Anticancer Therapy by Arad-Cohen, et al. They include...

Neutralizing antibody responses to SARS-CoV-2 in patients with AML or MDS

Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) represents an increased risk for patients with immune dysfunction...

Should COVID-19 vaccination be postponed after AML therapy?

During the 63rd ASH Annual Meeting and Exposition, the AML hub spoke with Sabine Haggenburg, Amsterdam UMC, Amsterdam, NL. We asked, Should...

EPICOVIDEHA registry: Epidemiology and outcomes in patients with hematologic malignancies infected with COVID-19

Patients with hematologic malignancies (HMs) may have intensified immune dysregulation...

Visual abstract | Azacitidine with venetoclax and magrolimab in patients with ND or R/R AML

We present a visual abstract representing key data from a phase I/II trial investigating the triplet...

How can outcomes be improved in patients with molecularly-defined high-risk AML?

During the 64th ASH Annual Meeting and Exposition, the AML Hub was pleased to speak to Alice Mims, Ohio State...

Latest insights on TP53 mutations in AML and MDS from ASH 2022

In this article, we summarize several presentations from the 64th ASH Annual Meeting and Exposition on TP53mut and the impact on survival...

Association between prior lenalidomide exposure and TP53-mutated therapy-related AML

The AML Hub summarizes a study that suggests prior exposure to lenalidomide is associated with the development of...